cached image

Joel S. Freundlich - Publications

Affiliations: 
2011- Pharmacology and Physiology Rutgers New Jersey Medical School 
Area:
Mycobacterium tuberculosis
Website:
http://njms.rutgers.edu/resource_locator/find_people/profile.cfm?mbmid=freundjs

66 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Jadhav R, Gallardo-Macias R, Kumar G, Daher SS, Kaushik A, Bigelow KM, Nuermberger EL, Lamichhane G, Freundlich JS. Assessment of carbapenems in a mouse model of Mycobacterium tuberculosis infection. Plos One. 16: e0249841. PMID 33939697 DOI: 10.1371/journal.pone.0249841  0.68
2020 Puhl AC, Lane TR, Vignaux PA, Zorn KM, Capodagli GC, Neiditch MB, Freundlich JS, Ekins S. Computational Approaches to Identify Molecules Binding to KasA. Acs Omega. 5: 29935-29942. PMID 33251429 DOI: 10.1021/acsomega.0c04271  0.68
2020 Perryman AL, Inoyama D, Patel JS, Ekins S, Freundlich JS. Pruned Machine Learning Models to Predict Aqueous Solubility. Acs Omega. 5: 16562-16567. PMID 32685821 DOI: 10.1021/acsomega.0c01251  0.68
2020 Smith TC, Pullen KM, Olson MC, McNellis ME, Richardson I, Hu S, Larkins-Ford J, Wang X, Freundlich JS, Ando DM, Aldridge BB. Morphological profiling of tubercle bacilli identifies drug pathways of action. Proceedings of the National Academy of Sciences of the United States of America. PMID 32680963 DOI: 10.1073/Pnas.2002738117  0.4
2020 Pereira JC, Daher SS, Zorn KM, Sherwood M, Russo R, Perryman AL, Wang X, Freundlich MJ, Ekins S, Freundlich JS. Machine Learning Platform to Discover Novel Growth Inhibitors of Neisseria gonorrhoeae. Pharmaceutical Research. 37: 141. PMID 32661900 DOI: 10.1007/S11095-020-02876-Y  0.68
2020 Inoyama D, Awasthi D, Capodagli GC, Tsotetsi K, Sukheja P, Zimmerman M, Li SG, Jadhav R, Russo R, Wang X, Grady C, Richmann T, Shrestha R, Li L, Ahn YM, ... ... Freundlich JS, et al. A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA. Cell Chemical Biology. PMID 32197094 DOI: 10.1016/J.Chembiol.2020.02.007  0.4
2019 Lane TR, Massey C, Comer JE, Anantpadma M, Freundlich JS, Davey RA, Madrid PB, Ekins S. Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection. Plos Neglected Tropical Diseases. 13: e0007890. PMID 31751347 DOI: 10.1371/Journal.Pntd.0007890  0.68
2019 Wang X, Inoyama D, Russo R, Li SG, Jadhav R, Stratton TP, Mittal N, Bilotta JA, Singleton E, Kim T, Paget SD, Pottorf RS, Ahn YM, Davila-Pagan A, Kandasamy S, ... ... Freundlich JS, et al. Antitubercular Triazines: Optimization and Intrabacterial Metabolism. Cell Chemical Biology. PMID 31711854 DOI: 10.1016/J.Chembiol.2019.10.010  0.68
2019 Wang X, Perryman A, Li SG, Paget S, Stratton T, Lemenze A, Olson AJ, Ekins S, Kumar P, Freundlich JS. Intrabacterial Metabolism Obscures the Successful Prediction of an InhA Inhibitor of Mycobacterium tuberculosis. Acs Infectious Diseases. PMID 31625383 DOI: 10.1021/Acsinfecdis.9B00295  0.68
2019 Lane T, Anantpadma M, Freundlich JS, Davey RA, Madrid PB, Ekins S. The Natural Product Eugenol Is an Inhibitor of the Ebola Virus In Vitro. Pharmaceutical Research. 36: 104. PMID 31101988 DOI: 10.1007/S11095-019-2629-0  0.68
2019 Anantpadma M, Lane T, Zorn KM, Lingerfelt MA, Clark AM, Freundlich JS, Davey RA, Madrid PB, Ekins S. Ebola Virus Bayesian Machine Learning Models Enable New in Vitro Leads. Acs Omega. 4: 2353-2361. PMID 30729228 DOI: 10.1021/acsomega.8b02948  0.68
2018 Gallardo-Macias R, Kumar P, Jaskowski M, Richmann T, Shrestha R, Russo R, Singleton E, Zimmerman MD, Ho HP, Dartois V, Connell N, Alland D, Freundlich JS. Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent. Bioorganic & Medicinal Chemistry Letters. PMID 30600207 DOI: 10.1016/J.Bmcl.2018.12.053  0.4
2018 Kumar P, Capodagli GC, Awasthi D, Shrestha R, Maharaja K, Sukheja P, Li SG, Inoyama D, Zimmerman M, Ho Liang HP, Sarathy J, Mina M, Rasic G, Russo R, Perryman AL, ... ... Freundlich JS, et al. Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA. Mbio. 9. PMID 30563908 DOI: 10.1128/Mbio.02101-17  0.68
2018 Mori G, Orena BS, Franch C, Mitchenall LA, Godbole AA, Rodrigues L, Aguilar-Pérez C, Zemanová J, Huszár S, Forbak M, Lane TR, Sabbah M, Deboosere N, Frita R, Vandeputte A, ... ... Freundlich JS, et al. The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase. Tuberculosis (Edinburgh, Scotland). 112: 98-109. PMID 30205975 DOI: 10.1016/J.Tube.2018.08.004  0.68
2018 Perryman AL, Patel JS, Russo R, Singleton E, Connell N, Ekins S, Freundlich JS. Naïve Bayesian Models for Vero Cell Cytotoxicity. Pharmaceutical Research. 35: 170. PMID 29959603 DOI: 10.1007/S11095-018-2439-9  0.68
2018 Lane T, Russo DP, Zorn KM, Clark AM, Korotcov A, Tkachenko V, Reynolds RC, Perryman AL, Freundlich JS, Ekins S. Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery. Molecular Pharmaceutics. PMID 29672063 DOI: 10.1021/Acs.Molpharmaceut.8B00083  0.68
2018 Inoyama D, Paget SD, Russo R, Kandasamy S, Kumar P, Singleton E, Occi J, Tuckman M, Zimmerman MD, Ho HP, Perryman AL, Dartois V, Connell N, Freundlich JS. Novel Pyrimidines as Antitubercular Agents. Antimicrobial Agents and Chemotherapy. PMID 29311070 DOI: 10.1128/Aac.02063-17  0.36
2018 Pshezhetsky AV, Pan X, Héon-Roberts R, Li S, Wu HY, Taherzadeh M, Aragão CDBPD, Wood J, Ekins S, Boyd R, Freundlich JS. Chaperone therapy for mucopolysaccharidosis type IIIC Molecular Genetics and Metabolism. 123. DOI: 10.1016/J.Ymgme.2017.12.329  0.68
2018 Ekins S, Clark AM, Perryman AL, Freundlich JS, Korotcov A, Tkachenko V. Accessible Machine Learning Approaches for Toxicology Computational Toxicology. 1-29. DOI: 10.1002/9781119282594.Ch1  0.68
2017 Stratton TP, Perryman AL, Vilchèze C, Russo R, Li SG, Patel JS, Singleton E, Ekins S, Connell N, Jacobs WR, Freundlich JS. Addressing the Metabolic Stability of Antituberculars through Machine Learning. Acs Medicinal Chemistry Letters. 8: 1099-1104. PMID 29057058 DOI: 10.1021/Acsmedchemlett.7B00299  0.68
2017 Kumar P, Chauhan V, Silva JRA, Lameira J, d'Andrea F, Li S, Ginell SL, Freundlich JS, Alves CN, Bailey S, Cohen KA, Lamichhane G. Mycobacterium abscessus L,D-transpeptidases are susceptible to inactivation by carbapenems and cephalosporins but not penicillins. Antimicrobial Agents and Chemotherapy. PMID 28760902 DOI: 10.1128/Aac.00866-17  0.68
2017 Sukheja P, Kumar P, Mittal N, Li SG, Singleton E, Russo R, Perryman AL, Shrestha R, Awasthi D, Husain S, Soteropoulos P, Brukh R, Connell N, Freundlich JS, Alland D. A Novel Small-Molecule Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells. Mbio. 8. PMID 28196957 DOI: 10.1128/Mbio.02022-16  0.4
2016 Kumar P, Kaushik A, Lloyd EP, Li SG, Mattoo R, Ammerman NC, Bell DT, Perryman AL, Zandi TA, Ekins S, Ginell SL, Townsend CA, Freundlich JS, Lamichhane G. Non-classical transpeptidases yield insight into new antibacterials. Nature Chemical Biology. PMID 27820797 DOI: 10.1038/Nchembio.2237  0.68
2016 Ekins S, Perryman AL, Clark AM, Reynolds RC, Freundlich JS. Machine Learning Model Analysis and Data Visualization with Small Molecules Tested in a Mouse Model of Mycobacterium tuberculosis Infection (2014-2015). Journal of Chemical Information and Modeling. PMID 27335215 DOI: 10.1021/Acs.Jcim.6B00004  0.68
2016 Ekins S, Mietchen D, Coffee M, Stratton TP, Freundlich JS, Freitas-Junior L, Muratov E, Siqueira-Neto J, Williams AJ, Andrade C. Open drug discovery for the Zika virus. F1000research. 5: 150. PMID 27134728 DOI: 10.12688/F1000Research.8013.1  0.68
2015 Ekins S, Freundlich JS, Clark AM, Anantpadma M, Davey RA, Madrid P. Machine learning models identify molecules active against the Ebola virus in vitro. F1000research. 4: 1091. PMID 26834994 DOI: 10.12688/F1000Research.7217.3  0.68
2015 Ekins S, Madrid PB, Sarker M, Li SG, Mittal N, Kumar P, Wang X, Stratton TP, Zimmerman M, Talcott C, Bourbon P, Travers M, Yadav M, Freundlich JS. Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Models for Mycobacterium tuberculosis Drug Discovery. Plos One. 10: e0141076. PMID 26517557 DOI: 10.1371/Journal.Pone.0141076  0.68
2015 Perryman AL, Stratton TP, Ekins S, Freundlich JS. Predicting Mouse Liver Microsomal Stability with "Pruned" Machine Learning Models and Public Data. Pharmaceutical Research. PMID 26415647 DOI: 10.1007/S11095-015-1800-5  0.68
2015 Li SG, Vilchèze C, Chakraborty S, Wang X, Kim H, Anisetti M, Ekins S, Rhee KY, Jacobs WR, Freundlich JS. Evolution of a thienopyrimidine antitubercular relying on medicinal chemistry and metabolomics insights. Tetrahedron Letters. 56: 3246-3250. PMID 26257441 DOI: 10.1016/J.Tetlet.2015.02.129  0.68
2015 Forbes L, Ebsworth-Mojica K, DiDone L, Li SG, Freundlich JS, Connell N, Dunman PM, Krysan DJ. A High Throughput Screening Assay for Anti-Mycobacterial Small Molecules Based on Adenylate Kinase Release as a Reporter of Cell Lysis. Plos One. 10: e0129234. PMID 26098625 DOI: 10.1371/Journal.Pone.0129234  0.68
2015 Clark AM, Dole K, Coulon-Spektor A, McNutt A, Grass G, Freundlich JS, Reynolds RC, Ekins S. Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets. Journal of Chemical Information and Modeling. 55: 1231-45. PMID 25994950 DOI: 10.1021/Acs.Jcim.5B00143  0.68
2015 Ekins S, Litterman NK, Arnold RJ, Burgess RW, Freundlich JS, Gray SJ, Higgins JJ, Langley B, Willis DE, Notterpek L, Pleasure D, Sereda MW, Moore A. A brief review of recent Charcot-Marie-Tooth research and priorities. F1000research. 4: 53. PMID 25901280 DOI: 10.12688/F1000Research.6160.1  0.68
2015 Perryman AL, Yu W, Wang X, Ekins S, Forli S, Li SG, Freundlich JS, Tonge PJ, Olson AJ. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA. Journal of Chemical Information and Modeling. 55: 645-59. PMID 25636146 DOI: 10.1021/Ci500672V  0.68
2014 Ekins S, Freundlich JS, Coffee M. A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus. F1000research. 3: 277. PMID 25653841 DOI: 10.12688/F1000Research.5741.2  0.68
2014 Al Olaby RR, Cocquerel L, Zemla A, Saas L, Dubuisson J, Vielmetter J, Marcotrigiano J, Khan AG, Vences Catalan F, Perryman AL, Freundlich JS, Forli S, Levy S, Balhorn R, Azzazy HM. Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein. Plos One. 9: e111333. PMID 25357246 DOI: 10.1371/Journal.Pone.0111333  0.68
2014 Stec J, Vilchèze C, Lun S, Perryman AL, Wang X, Freundlich JS, Bishai W, Jacobs WR, Kozikowski AP. Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis. Chemmedchem. 9: 2528-37. PMID 25165007 DOI: 10.1002/Cmdc.201402255  0.68
2014 Ekins S, Nuermberger EL, Freundlich JS. Minding the gaps in tuberculosis research. Drug Discovery Today. 19: 1279-82. PMID 24993157 DOI: 10.1016/J.Drudis.2014.06.022  0.68
2014 Ekins S, Freundlich JS, Reynolds RC. Are bigger data sets better for machine learning? Fusing single-point and dual-event dose response data for Mycobacterium tuberculosis. Journal of Chemical Information and Modeling. 54: 2157-65. PMID 24968215 DOI: 10.1021/Ci500264R  0.68
2014 Nixon MR, Saionz KW, Koo MS, Szymonifka MJ, Jung H, Roberts JP, Nandakumar M, Kumar A, Liao R, Rustad T, Sacchettini JC, Rhee KY, Freundlich JS, Sherman DR. Folate pathway disruption leads to critical disruption of methionine derivatives in Mycobacterium tuberculosis. Chemistry & Biology. 21: 819-30. PMID 24954008 DOI: 10.1016/J.Chembiol.2014.04.009  0.68
2014 Ekins S, Pottorf R, Reynolds RC, Williams AJ, Clark AM, Freundlich JS. Looking back to the future: predicting in vivo efficacy of small molecules versus Mycobacterium tuberculosis. Journal of Chemical Information and Modeling. 54: 1070-82. PMID 24665947 DOI: 10.1021/Ci500077V  0.68
2014 Ekins S, Freundlich JS, Hobrath JV, Lucile White E, Reynolds RC. Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery. Pharmaceutical Research. 31: 414-35. PMID 24132686 DOI: 10.1007/S11095-013-1172-7  0.68
2014 Ponder EL, Freundlich JS, Sarker M, Ekins S. Computational models for neglected diseases: gaps and opportunities. Pharmaceutical Research. 31: 271-7. PMID 23990313 DOI: 10.1007/S11095-013-1170-9  0.68
2013 Afanador GA, Muench SP, McPhillie M, Fomovska A, Schön A, Zhou Y, Cheng G, Stec J, Freundlich JS, Shieh HM, Anderson JW, Jacobus DP, Fidock DA, Kozikowski AP, Fishwick CW, et al. Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay. Biochemistry. 52: 9155-66. PMID 24295325 DOI: 10.1021/Bi400945Y  0.68
2013 Ekins S, Freundlich JS, Reynolds RC. Fusing dual-event data sets for Mycobacterium tuberculosis machine learning models and their evaluation. Journal of Chemical Information and Modeling. 53: 3054-63. PMID 24144044 DOI: 10.1021/Ci400480S  0.68
2013 Wilson R, Kumar P, Parashar V, Vilchèze C, Veyron-Churlet R, Freundlich JS, Barnes SW, Walker JR, Szymonifka MJ, Marchiano E, Shenai S, Colangeli R, Jacobs WR, Neiditch MB, Kremer L, et al. Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis. Nature Chemical Biology. 9: 499-506. PMID 23770708 DOI: 10.1038/Nchembio.1277  0.68
2013 Ekins S, Reynolds RC, Franzblau SG, Wan B, Freundlich JS, Bunin BA. Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models. Plos One. 8: e63240. PMID 23667592 DOI: 10.1371/Journal.Pone.0063240  0.68
2013 Ekins S, Freundlich JS. Computational models for tuberculosis drug discovery. Methods in Molecular Biology (Clifton, N.J.). 993: 245-62. PMID 23568475 DOI: 10.1007/978-1-62703-342-8_16  0.68
2013 Ekins S, Reynolds RC, Kim H, Koo MS, Ekonomidis M, Talaue M, Paget SD, Woolhiser LK, Lenaerts AJ, Bunin BA, Connell N, Freundlich JS. Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery. Chemistry & Biology. 20: 370-8. PMID 23521795 DOI: 10.1016/j.chembiol.2013.01.011  0.68
2013 Anderson JW, Sarantakis D, Terpinski J, Kumar TR, Tsai HC, Kuo M, Ager AL, Jacobs WR, Schiehser GA, Ekins S, Sacchettini JC, Jacobus DP, Fidock DA, Freundlich JS. Novel diaryl ureas with efficacy in a mouse model of malaria. Bioorganic & Medicinal Chemistry Letters. 23: 1022-5. PMID 23313245 DOI: 10.1016/J.Bmcl.2012.12.022  0.68
2012 Krieger IV, Freundlich JS, Gawandi VB, Roberts JP, Gawandi VB, Sun Q, Owen JL, Fraile MT, Huss SI, Lavandera JL, Ioerger TR, Sacchettini JC. Structure-guided discovery of phenyl-diketo acids as potent inhibitors of M. tuberculosis malate synthase. Chemistry & Biology. 19: 1556-67. PMID 23261599 DOI: 10.1016/J.Chembiol.2012.09.018  0.68
2012 Sarker M, Talcott C, Madrid P, Chopra S, Bunin BA, Lamichhane G, Freundlich JS, Ekins S. Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis. Pharmaceutical Research. 29: 2115-27. PMID 22477069 DOI: 10.1007/S11095-012-0741-5  0.68
2011 Vilchèze C, Baughn AD, Tufariello J, Leung LW, Kuo M, Basler CF, Alland D, Sacchettini JC, Freundlich JS, Jacobs WR. Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions. Antimicrobial Agents and Chemotherapy. 55: 3889-98. PMID 21628538 DOI: 10.1128/Aac.00266-11  0.68
2011 Ekins S, Freundlich JS. Validating new tuberculosis computational models with public whole cell screening aerobic activity datasets. Pharmaceutical Research. 28: 1859-69. PMID 21547522 DOI: 10.1007/s11095-011-0413-x  0.68
2011 Ekins S, Williams AJ, Krasowski MD, Freundlich JS. In silico repositioning of approved drugs for rare and neglected diseases. Drug Discovery Today. 16: 298-310. PMID 21376136 DOI: 10.1016/j.drudis.2011.02.016  0.68
2011 Lamichhane G, Freundlich JS, Ekins S, Wickramaratne N, Nolan ST, Bishai WR. Essential metabolites of Mycobacterium tuberculosis and their mimics. Mbio. 2: e00301-10. PMID 21285434 DOI: 10.1128/Mbio.00301-10  0.68
2011 Ekins S, Freundlich JS, Choi I, Sarker M, Talcott C. Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery. Trends in Microbiology. 19: 65-74. PMID 21129975 DOI: 10.1016/j.tim.2010.10.005  0.68
2011 Lotesta SD, Liu J, Yates EV, Krieger I, Sacchettini JC, Freundlich JS, Sorensen EJ. Expanding the pleuromutilin class of antibiotics by de novo chemical synthesis Chemical Science. 2: 1258-1261. DOI: 10.1039/c1sc00116g  0.68
2010 Freundlich JS, Lalgondar M, Wei JR, Swanson S, Sorensen EJ, Rubin EJ, Sacchettini JC. The abyssomicin C family as in vitro inhibitors of Mycobacterium tuberculosis. Tuberculosis (Edinburgh, Scotland). 90: 298-300. PMID 20739223 DOI: 10.1016/J.Tube.2010.08.002  0.68
2009 Palaninathan SK, Mohamedmohaideen NN, Orlandini E, Ortore G, Nencetti S, Lapucci A, Rossello A, Freundlich JS, Sacchettini JC. Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis. Plos One. 4: e6290. PMID 19621084 DOI: 10.1371/Journal.Pone.0006290  0.68
2009 Freundlich JS, Wang F, Vilchèze C, Gulten G, Langley R, Schiehser GA, Jacobus DP, Jacobs WR, Sacchettini JC. Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. Chemmedchem. 4: 241-8. PMID 19130456 DOI: 10.1002/Cmdc.200800261  0.68
2008 Yu M, Kumar TR, Nkrumah LJ, Coppi A, Retzlaff S, Li CD, Kelly BJ, Moura PA, Lakshmanan V, Freundlich JS, Valderramos JC, Vilcheze C, Siedner M, Tsai JH, Falkard B, et al. The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host & Microbe. 4: 567-78. PMID 19064257 DOI: 10.1016/J.Chom.2008.11.001  0.68
2008 Sacchettini JC, Rubin EJ, Freundlich JS. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nature Reviews. Microbiology. 6: 41-52. PMID 18079742 DOI: 10.1038/Nrmicro1816  0.68
2007 Freundlich JS, Wang F, Tsai HC, Kuo M, Shieh HM, Anderson JW, Nkrumah LJ, Valderramos JC, Yu M, Kumar TR, Valderramos SG, Jacobs WR, Schiehser GA, Jacobus DP, Fidock DA, et al. X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy. The Journal of Biological Chemistry. 282: 25436-44. PMID 17567585 DOI: 10.1074/Jbc.M701813200  0.68
2006 Freundlich JS, Yu M, Lucumi E, Kuo M, Tsai HC, Valderramos JC, Karagyozov L, Jacobs WR, Schiehser GA, Fidock DA, Jacobus DP, Sacchettini JC. Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2'-substituted triclosan derivatives. Bioorganic & Medicinal Chemistry Letters. 16: 2163-9. PMID 16466916 DOI: 10.1016/J.Bmcl.2006.01.051  0.68
2006 Freundlich JS, Landis HE. An expeditious aqueous Suzuki-Miyaura method for the arylation of bromophenols Tetrahedron Letters. 47: 4275-4279. DOI: 10.1016/j.tetlet.2006.04.027  0.68
2005 Freundlich JS, Anderson JW, Sarantakis D, Shieh HM, Yu M, Valderramos JC, Lucumi E, Kuo M, Jacobs WR, Fidock DA, Schiehser GA, Jacobus DP, Sacchettini JC. Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4'-substituted triclosan derivatives. Bioorganic & Medicinal Chemistry Letters. 15: 5247-52. PMID 16198563 DOI: 10.1016/J.Bmcl.2005.08.044  0.68
Show low-probability matches.